Jonathan Wosen, a seasoned colleague in oncology research, shares insights on the latest shifts in the life sciences. The conversation highlights Genentech's decision to close its cancer immunology division and the reaction from the biotech community. Wosen also discusses Pfizer’s withdrawal of its sickle cell treatment and the implications for future drug approvals. Additionally, they explore the promising prospects of a new schizophrenia drug set to be approved, emphasizing the urgent need for innovative therapies in mental health.

Jonathan Wosen discusses biotech layoffs, while Alexis Borisy and Zach Weinberg talk about their biotech incubator Curie.Bio. The podcast also covers Pfizer's leadership change and a new side effect of the diabetes drug Ozempic.

In this engaging discussion, gene therapy pioneer Jim Wilson, known for his groundbreaking work at the University of Pennsylvania, shares insights on his recent departure and future plans. Joining him is Jonathan Wosen, a biotech reporter, who sheds light on the surprising closure of a gene editing company and the challenges facing the industry. They explore Eli Lilly's new pricing strategy for its obesity drug, Zepbound, and the shift toward direct-to-consumer sales. The conversation captures the dynamic, often unpredictable nature of biotech today.